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Abstract CD133 has played a pivotal role in the identi-
fication and isolation of brain tumor stem cells. The cor-
relation between CD133 expression in tumor tissues with
patients survival is still controversial. CD133 expression is
determinated by methylation status of the promoter region
1–3. Aberrant methylation of CD133 was observed in
glioblastoma. To date, a direct link between CD133
methylation and patient outcome has not been estab-
lished.To address this question, we studied CD133
expression and promoter methylation in a series of 170
gliomas of various grade and histology, and investigated
the correlation of CD133 expression and promoter
methylation with patient outcome.We detected five CD133
promoter methylation patterns in 170 glioma samples:
methylation only (M?, U-), unmethylation only (M-,
U?), both methylation and unmethylation equally (M?,
U?), high methylation and low unmethylation (M?, Ul),
and low methylation and high unmethylation (Ml, U?). By
multivariate survival analysis, we found CD133 promoter
methylation status was significant (P\ 0.01) prognostic
factors for adverse progression-free survival and overall
survival independent of tumor grade, extent of resection, or
patient age. CD133 immunostaining showed considerable
variability among tumors. While, there was lack of corre-
lation between CD133 protein expression and patient’s
survival. Furthermore, no correlation between CD133
protein expression and CD133 promoter methylation status
was observed (Kw = -0.165).CD133 promoter methyla-
tion status in glioma is closely correlated with patient
survival, which suggest CD133 promoter methylaiton pat-
tern is a promising tool for diagnostic purposes.
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Introduction
Increasing evidence suggests that there is a small subset of
cells, called cancer stem cells (CSC), that are responsible
for cancer initiation and development [1]. The CSC model
of tumor development suggests that the clinical behavior of
a tumor will be largely determined by a subpopulation of
cells that are characterized by their ability to initiate new
tumors [2]. Recently, CSC has been described in several
solid tumors,including brain tumors [3, 4]. These studies
used putative stem cell markers or side populations to
isolate unique subsets of cancer cells from different types
of tumors. These markers included CD24, CD44, CD133,
and CD166 that are also expressed in normal cells. Among
these markers, CD133 were widely used for isolating CSC
from solid tumors [5–8].
Surface membrane protein CD133, which is normally
expressed in a subset of putative neural stem/precursor
cells in the normal brain, have been identified in brain
tumors [4, 5, 9, 10]. CD133-positive tumor cells can ini-
tiate neurospheres, which exhibit self-renewal, differenti-
ation, and proliferation resembling that of normal NSCs.
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The transplantation of CD133-positive tumor cells into
nonobese diabetic/severe combined immunodeficient mice
is sufficient to produce tumors phenotypically identical to
the patient’s original tumors [4, 11]. CD133-positive
glioma cells were also reported to possess enhanced
chemoresistance and radioresistance, resulting in tumor
progression and recurrence [12–15]. Therefore, the regu-
latory mechanisms of CD133 expression could help to
elucidate the development of gliomas.
Changes in DNA methylation patterns are an important
hallmark of tumor development and progression [16].
Although the role of hypermethylation in the silencing of
tumor suppressor genes is now well-documented, abnormal
methylation contributes to neoplastic progression in
numerous types of human cancer, including glioblastomas
[17–19]. CD133 expression in glioblastomas is determi-
nated by methylation status of the promoter region 1–3
in vitro [20]. Strong methylation of CD133 promoter dis-
played in CD133-negative tumor cells, but less in the
CD133-positive fraction [21]. Surprisingly, however, apart
from the observation of aberrant methylation of CD133 in
glioblastoma [21], a direct link between CD133 methyla-
tion and patient outcome thus far has not been established.
To address this question, we studied CD133 expression and
promoter methylation in gliomas, and investigated the




One hundred and seventy glioma samples used for this
study were derived from formalin-fixed and paraffin-
embedded surgical tissue samples obtained from the
archive of Department of Neuropathology, Huashan
Hospital, Fudan University, with approval from the insti-
tutional review board. This study compiles data for glioma
of tumor stages II to IV (n = 170) and normal brain con-
trols (n = 3). Three noncancer brain tissues used in this
study were also obtained from the Neural Stem Cell Lab-
oratory at Huashan Hospital, with institutional review
board approval. Tumors were histopathologically classified
according to the WHO classification. Informed consent was
obtained from each patient according to the research pro-
posals approved by the Institutional Review Board at the
Medical Faculty Shanghai. Eligibility criteria included
written informed consent and availability of tumor tissue
and of follow-up data. Clinical information was obtained
by reviewing the medical records on radiographic images,
by telephone, and by review of death certificate. Patient
data were analyzed after a mean follow-up period of 134.3
(±90.5) weeks. The demographic and clinical characteris-
tics of the patients are showed in Table 1.
Methylation-specific PCR
Genomic DNA was isolated from paraffin embedded
samples DNA was extracted using QIAamp DNA FFPE
Tissue Kit(Qiagen). Bisulfite modification of genomic
DNA was carried out using the EZ DNA methylation kit
(Zymo Research). For PCR amplification, primer sequen-
ces for methylation-specific PCR (MSP) analysis were
designed using MSP Primer. We performed methylation
analysis of the CD133 promoter using MSP primer pairs
covering the putative transcriptional start site in the 5 CpG
island with 1 lL of bisulfite-treated DNA as template and
ZymoTaq DNA polymerase (Zymo Research) for amplifi-
cation, as previously described. The annealing temperature

















II 62 40/22 A/2 55 41(2–70) 195a (11–308) 41/55 196(2–308) 45/55
O/2 7 48(9–65) 232 (84–310) 1/7 232(150–310) 1/7
III 29 18/11 AA/3 28 48.5(19–69) 69b (6–306) 8/28 101(2–355) 8/28
OA/3 1 22 145 0/1 175 1/1
IV 79 52/27 pGBM 73 53(11–79) 29c (11–242) 6/73 66(2–242) 9/73
sGBM 6 45.5(38–61) 14d (9–24) 1/6 41(15–87) 0/6
n case number; M male, F female, LO last observation, A astrocytoma, O oligodendroglioma, AA anaplastic astrocytoma, AO anaplastic
oligodendroglioma, pGBM primary glioblastoma, sGBM secondary glioblastoma
a PFS of two patients could not be assessed
b PFS of two patients could not be assessed
c PFS of thirteen patients could not be assessed
d PFS of one patients could not be assessed
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was 58 C. All reactions were done twice to exclude
unspecific PCR amplifications. Normal human lymphocyte
DNA was used as negative control for methylated alleles of
CD133, and placental DNA treated in vitro with SssI
methyltransferase (New England Biolabs) was used as
positive control. Controls without DNA were used for each
set of MSP assay. PCR products were separated on 3 %
agrose gels, stained with ethidium bromide, and examined
under UV illumination. CD133 promoter methylation pat-
terns were methylation only (M?, U-), unmethylation
only (M-, U?), both methylation and unmethylation
equally (M?, U?), high methylation and low unmethyla-
tion (M?, Ul), and low methylation and high unmethyla-
tion (Ml, U?). Investigators doing these assays were
blinded to clinical information.
Immunohistochemistry
Paraffin Sects. (5–7 lm) were stained for CD133 using a
mouse monoclonal anti-CD133 antibody originally used to
enrich tumorigenic CD133-positive cells from gliomas as
well as an isotype IgG2b control antibody (both Miltenyi
Biotec). Fixation and staining were carried out as described
[22]. CD133 staining data were obtained from at least two
sections per tissue. Immunohistochemically stained slides
were reviewed by two investigators independent from one
another and blinded to all clinical data. CD133 staining of
the whole tissue section was semiquantitatively graded for
percentage of cells stained in n.d. (not detectable) or\1, 1
to 10, 10 to 50, and [50 % CD133-positive cells per
section.
Correlation of CD133 IHC results with MSP results
Weighted kappa (Kw) was used to evaluate agreement
between CD133 promoter methylation status and
immunohistochemically evaluated CD133 expression in
tumor cells. For this purpose, we categorized the
immunohistochemical CD133 values in ordinal as previous
described: n.d. (not detectable) or\1, 1 to 10, 10 to 50, and
[50 %. Kw values lie between zero (absence of agree-
ment) and 1 (absolute agreement). Observed values of Kw
were considered satisfactory if equal to or greater than
0.80.
Statistical analysis
Progression-free survival (PFS) was calculated from the
date of surgery until the date of documented tumor recur-
rence or further growth of residual tumor and defined as
‘‘tumor regrowth’’. Overall survival was defined from the
day of surgery until death of the patient. For patients who
had not experienced recurrence or death at the time of last
follow-up, PFS and overall survival (OS) were censored at
the date of last follow-up. In case of impossible patient
contact, the last date of visit was taken as provisional end
point to allow statistical analysis. The association between
PFS or OS and CD133 expression or CD133 promoter
methylation status was calculated using log-rank tests and
presented as Kaplan–Meier plots. Furthermore, a multi-
variate analysis was done by using Cox proportional haz-
ards regression to determine the prognostic effect of
CD133 expression, CD133 methylation status and potential
clinical variables (age, WHO grade, and extent of resec-
tion) on OS and PFS. Backward selection applying a
stopping rule based on the Akaike information criterion
was used to exclude redundant or unnecessary variables.
For continuous variables, the cutoff level chosen was their
median value. CD133 immunohistochemistry was reclas-
sified as\1 and[1 % (including low, moderate, and high
staining) for statistical purposes. Hazard ratios (HR) and
their corresponding 95 % confidence intervals (95 % CI)
were computed to provide quantitative information about
the relevance of results of the statistical analysis. The
relationship between tumor CD133 expression and MSP
results were evaluated by the Cohen’s weighted kappa
statistics. All statistical analyses were performed using
SAS9.2 statistical software (SAS Institute Inc., N.C.).
Statistical significance was set at the level of P\ 0.05.
Results
CD133 promoter methylation status and patient
prognosis
We first investigated the CD133 promoter methylation
status in three normal brain samples. As previous study
showed [22], CD133 promoter were unmethylated in all
normal brain using samples from noncancer patient tissue.
Then, we explored the methylation pattern of CD133
promoter in different grade gliomas (Fig. 1). Methylation
of the CD133 promoter was found in 106 of the 170 tumors
(62.4 %). The distribution of CD133 methylation among
the different patients’ characteristics is shown in Table 2.
The presence of CD133 CpG island methylation in glioma
patients was not associated with the sex (P = 0.26) or age
of the patient (P = 0.19), but associated with the histo-
logical type of the tumor (P = 0.005) and grades
(P = 0.005). In low-grade tumors (WHO grade 2), the
percentage of methylated and unmethylated CD133 were
74.2 % (46 of 62) and 25.8 % (16 of 62), respectively.
With the progression to GBM (WHO grade 4), the per-
centage of methylation decreased to 49.4 % (39 of 79), and
the percentage of unmethylation increased to 50.6 % (40 of
79).
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To investigate the effect of CD133 promoter methyla-
tion status on patient outcome, corresponding PFS and OS
data were assessed from the study sample. PFS could not
be assessed in eithteen. PFS and OS depending on various
clinical variables and CD133 methylation status are sum-
marized in Table 3. In univariate analyses, methylation of
the promoter was positively correlated with PFS and OS.
The PFS and OS of patients with unmethylated CD133
promoter was 91.0 weeks (95 % CI, 61.3–120.8) and
113.7 weeks (95 % CI, 87.1–140.3), respectively. While,
patients with methylated CD133 promoter showed a ten-
dency to an increased PFS (189.7 weeks, 95 % CI,
164.1–215.3) and OS (218.9 weeks, 95 % CI,
200.4–271.6). Such analysis indicated a strong correlation
between CD133 promoter methylation status and both
overall (P = 0.002) and progression-free (P\ 0.001) sur-
vival (Fig. 2), suggesting that CD133 methylation of
tumorigenic cells is associated with a more favorable
prognosis. The importance of CD133 methylation as a
prognostic factor was next determined by the Cox pro-
portional hazards model analysis. Multivariate analysis
confirmed CD133 methylation (HR 2.87; 95 % CI,
1.74–4.73; P\ 0.001) as significant prognostic factors for
longer OS, independent of WHO grade, age, and extent of
Fig. 1 a Methylation analysis of the CD133 gene in primary glioma
tissues. The MSP production of methylated and unmethylated CD133
are 105 and 118 bp, respectively. M methylation signal, U unmethy-
lated signal, MPBL methylated peripheral blood lymphocyte DNA,
PBL peripheral blood lymphocyte DNA, ddH2O water control adding
no DNA. b CD133 methylation status in 170 gliomas differing in
histology and WHO grade. CD133 promoter methylation patterns
were methylation only (M?, U-), unmethylation only (M-, U?),
both methylation and unmethylation equally (M?, U?), high
methylation and low unmethylation (M?, Ul), and low methylation
and high unmethylation (Ml, U?). AII astrocytoma grade II, OII
oligodendroglioma grade II, AAIII anaplastic astrocytoma grade III,
AOIII anaplastic oligodendroglioma grade III
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resection; similar results were obtained for PFS and
methylation of CD133 (HR 2.61; 95 % CI, 1.57–4.34;
P\ 0.001).
Furthermore, we have investigated the effect of CD133
promoter methylation status on patient outcome by strati-
fying with tumor grades, corresponding PFS and OS data
were assessed in LGG (low grade glioma, WHO 2) and
HGG (high grade glioma, WHO 3 or 4) patients. PFS could
not be assessed in two patients in LGG, and 16 patients in
HGG. The PFS and OS of LGG patients with unmethylated
CD133 promoter was 197.1 weeks (95 % CI, 132.5–261.8)
and 209.6 weeks (95 % CI, 150.1–269.1), respectively.
While, patients with methylated CD133 promoter showed a
tendency to an increased PFS (271.0 weeks, 95 % CI,
235.7–306.3) and OS (286.2 weeks, 95 % CI,
260.5–311.9). Such analysis indicated a strong correlation
between CD133 promoter methylation status and both
overall (P = 0.008) and progression-free (P = 0.035) sur-
vival, suggesting that CD133 methylation of tumorigenic
cells is associated with a more favorable prognosis in LGG
patients. The PFS and OS of HGG patients with
unmethylated CD133 promoter was 47.7 weeks (95 % CI,
29.3–66.1) and 77.1 weeks (95 % CI, 58.7–95.4), respec-
tively. While, patients with methylated CD133 promoter
showed a tendency to an increased PFS (139.5 weeks,
95 % CI, 100.5–178.5) and OS (172.2 weeks, 95 % CI,
128.8–215.7). Such analysis indicated a strong correlation
between CD133 promoter methylation status and both
overall (P\ 0.01) and progression-free (P\ 0.01) sur-
vival, suggesting that CD133 methylation of tumorigenic
cells is also associated with a more favorable prognosis in
HGG patients.
Degree CD133 expression in glioma tissues
Expression of the CD133 antigen was assessed by
immunohistochemistry in paraffin-embedded sections in a
panel of 130 gliomas of different WHO grades and his-
tologies. CD133 immunostaining showed considerable
variability among tumors ranging from complete lack of
immunoreactivity (Fig. 3a, d, g) to expression in single
cells (Fig. 3b, e, h) or staining of cell clusters (Fig. 3c, f, i).
CD133 positive immunostaining was detected in 37 tumors
(28.5 %). In all positive tumor samples, heterogenous
immunostaining was observed; areas with complete loss of
CD133 expression alternated with areas of scattered or
clustered cells with strong immunoreactivity. Surprisingly,
further analysis showed there were no correlations between
CD133 expressions with WHO grades (Fig. 2). CD133
negative and\1 % of tumor cells were predominant in all
grades of gliomas. 24.5 % (12/49) of grade 2 gliomas were
found to express CD133 over 10 %. With progression to
Table 2 The CD133 methylation pattern of the glioma patients




Female 26 34 0.26
Age
\ 45 23 51
45–59 27 41








IV 40 39 0.005
Table 3 Multivariate analysis
of prognostic factors as
covariables with CD133
methylaiton status or expression
for glioma outcome
Variable PFS OS
HR (95 % CI) p HR (95 % CI) p
CD133 methylation status n = 152 n = 170
Unmethylation 1 1
Methylation 2.61 (1.57–4.34) \0.001 2.87 (1.74–4.73) \0.001
WHO grade
WHO2 1 1
WHO3 4.49 (2.14–9.38) \0.001 7.06 (3.34–14.91) \0.001
WHO4 7.74 (3.90–15.33) \0.001 11.51 (5.86–22.61) \0.001
Patient age 1.021(1.00–1.04) 0.016 – 0.054
Extent of resection 0.72 (0.55–0.94) 0.016 1.40 (0.71–2.76) 0.330
Backword stepwise (likelihood ratio) Cox regression model
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Fig. 2 Kaplan–Meier plots showing a correlation of CD133 methy-
lation status with PFS and OS. a The Kaplan–Meier plots of CD133
methylation status. The PFS and OS of patients with unmethylated
CD133 promoter was 91.0 weeks (95 % CI, 61.3–120.8) and
113.7 weeks (95 % CI, 87.1–140.3), respectively. While, patients
with methylated CD133 promoter showed a tendency to an increased
PFS (189.7 weeks, 95 % CI, 164.1–215.3) and OS (218.9 weeks,
95 % CI, 200.4–271.6). b The Kaplan–Meier plots of CD133
methylation status in LGG. The PFS and OS of LGG patients with
unmethylated CD133 promoter was 197.1 weeks (95 % CI,
132.5–261.8) and 209.6 weeks (95 % CI, 150.1–269.1), respectively.
While, patients with methylated CD133 promoter showed a tendency
to an increased PFS (271.0 weeks, 95 % CI, 235.7–306.3) and OS
(286.2 weeks, 95 % CI, 260.5–311.9). c The Kaplan–Meier plots of
CD133 methylation status in HGG.The PFS and OS of HGG patients
with unmethylated CD133 promoter was 47.7 weeks (95 % CI,
29.3–66.1) and 77.1 weeks (95 % CI, 58.7–95.4), respectively.
While, patients with methylated CD133 promoter showed a tendency
to an increased PFS (139.5 weeks, 95 % CI, 100.5–178.5) and OS
(172.2 weeks, 95 % CI, 128.8–215.7)
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anaplastic gliomas (WHO grade 3) and GBM (WHO grade
4), the percentage of CD133 over 10 % decrease to 15.0 %
(3 of 20) and 11.5 % (7 of 61), which seems opposite to
grade of gliomas.
To investigate the effect of proportion of CD133 posi-
tive cells on patient outcome, corresponding PFS and OS
data were assessed from the study sample. Univariate
analysis documents there was no correlation of PFS and OS
with the numbers of CD133-positive cells (Fig. 3k, l).
CD133 promoter methylation status and cd133
protein expression
After demonstrating there was lacking of correlation
between CD133 protein expression and histological grades,
we investigated relationship of CD133 protein expression
and CD133 MSP(methylated or unmethylated) in glioma
samples(Fig. 4). We categorized the immunohistochemical
CD133 values in three different ways (see also Materials
and Methods): (i) CD133 negative (\1 %) versus CD133
positive; (ii) Low ([1 and\10 %) versus high ([10 and
\50 %) CD133 expression; (iii) CD133 expression in
\50 % of tumor cells versus CD133 expression in[50 %
of tumor cells. We found poor to slight agreement between
MSP and CD133 IHC at all categories (Kw = -0.165).
Discussion
CD133 has played a pivotal role in the identification and
isolation of brain tumor stem cells. However, the correla-
tion between CD133 expression in tumor tissues with
patients survivals is still controversial [23, 24]. This study
represents, to our knowledge, the first investigation aimed
at evaluating the prognostic significance of CD133 in a
series of patients with gliomas in which both tumor CD133
expression and promoter methylation status were simulta-
neously evaluated. Our results show that CD133 promoter
methylation is independently associated with a longer
overall survival in patients with anaplastic gliomas,
whereas CD133 expression in IHC has no prognostic
implications. The strength of these results relies mainly on
the fact that CD133 predictive value has been evaluated
after adjusting this variable for well-recognized clinico-
pathologic prognostic factors.
In our study, CD133 methylation pattern was hetero-
geneous, ranging from unmethylation to methylation. Dif-
ferences in the methylation status of the CD133 promoter
in tumor cell subpopulations may explain this hetero-
geneity. Other potential explanations for this variability
include monoallelic promoter methylation, or loss of
heterozygosity in 4p15. Whereas the presence of contam-
inating normal cells may not be ruled out. The presence of
CD133 CpG island methylation in glioma patients was
associated with grades of glioma. In low-grade tumors
(WHO grade 2), the percentage of methylated and
unmethylated CD133 were 74.2 % (46 of 62) and 25.8 %
(16 of 62), respectively. With the progression to high grade
glioma (WHO grade 3 and 4), the percentage of methyla-
tion decreased to 44.4 % (62 of 108), and the percentage of
unmethylation increased to 55.6 % (60 of 108). This
findings was consistent with the others study, which
reported that promoter methylation of CD133 was lower in
advanced colorectal carcinomas and aggressive breast
cancer [25, 26]. This is concordant with the biologically
aggressive nature of high grade glioma, poor overall
prognosis, and limited therapeutic targets. More important,
our study first reported that the methylation status of the
CD133 promoter may have prognostic value. We found
CD133 hypermethylation to be significantly (almost two-
fold) more common in long-term survivors (74 %) as
compared to in short-term survivors (43 %) not only in
high grade glioma, but in low grade glioma. Multivariate
analysis indicated CD133 methylation was a significant
prognostic factor in gliomas, independent of tumor grade,
extent of resection, and patient age. This findings may
suggest that methylation of CD133 promoter may directly
relevant to the stem cell state of CSC. In recent study,
Gopisetty et al. demonstrate a role for the promoter CpG
island in critically regulating CD133 expression in glioma
stem cell (GSC) [27]. When the GSC cells were sorted into
CD133?ve and -ve fractions, CD133?ve cells are sig-
nificantly resistant to chemotherapeutic agents compared
with autologous CD133-ve cells and to radiation therapy.
CD133 promoter was hypermethylated in CD133-ve GSC
and glioma cells, but unmethylated in CD133?ve ones.
Promoter methylation of CD133-ve fraction can be
reversible by demethylation agents and reproduced CD133
strongly supporting a functional role for methylation in the
repression of CD133.
In the present study, a heterogeneous staining pattern of
CD133 was observed within the individual tumor and
between different tumors of the same grade. This is in
agreement with other studies which show expression of
CD133 was considerable various in gliomas on frozen
section [23, 28] and by flow cytometry [4]. We found that
85.0 % of the anaplastic astrocytomas and 75.4 % of the
glioblastomas were negative for CD133, which was much
lower than that of other studies who found that less than
40 % of anaplastic gliomas and less than 2 % of
glioblastomas were negative for CD133 [23, 24]. Use of
different CD133 antibody clones might explain the differ-
ence between our findings and the results obtained in other
studies. In other studies, the monoclonal antibody clone
AC133 and W6B3C1 were from Miltenyi Biotec [3, 29],
and goat polyclonal antibody was from Santa Cruz were
J Neurooncol (2016) 127:221–232 227
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Fig. 3 CD133 staining was also
observed in dispersed single
cells, a few large pleomorphic




tumors ranging from complete
lack of immunoreactivity (a, d,
g) to expression in single cells
(b, e, h) or staining of cell
clusters (c, f, i). Scale bar
25 lm. j CD133 staining pattern
in 130 gliomas differing in
histology and WHO grade. k,
l Kaplan–Meier plots showing
no correlation of CD133
staining pattern with PFS
(k) and OS (l)
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Fig. 4 No correlation between
CD133 protein expression and
CD133 promoter methylation
status. a, b CD133 promoter
was totally methylated, some
degree of CD133
immunoreactivity was still
detected. c, d CD133 expression
was completely lost, CD133
promoter was universally
unmethylated. e, f CD133
expression was either
completely negative or over
50 % in those samples of which
CD133 promoter methylation
pattern was both methylation
and unmethylation. The
relationship between tumor
CD133 expression and MSP
results were evaluated by the
Cohen’s weighted kappa
statistics, which showed no
correlation between CD133
protein expression and CD133
promoter methylation status
(Kw = -0.165)
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used [28], whereas we used the monoclonal antibody clone
CD133-1 from Miltenyi Biotec. Another explanation was
use of different tissue fixation methods. In other studies,
cryosections were used to stain CD133, whereas we used
formalin-fixed paraffin sections because the morphology is
better preserved in paraffin sections making it easier to
evaluate a membrane staining like CD133 [29].
Comparing the CD133 expression assessed by ICH with
overall patient, we found CD133 protein expression in
glioma was insufficient correlated with patient survival.
Therefore, in our study, CD133 IHC does not prove to be a
clinically usable tool in the prognostic assessment of
glioma. Previously published studies on diffuse glioma [23,
30, 31] reported a significant association of immunohisto-
chemically assessed CD133 expression and patient sur-
vival. However, this association was not confirmed our
present study in a larger patient cohort. This result may be
explained by the bona fide cancer stem cell being a sub-
population of the CD133? tumor cells, but it is also likely
that other non tumor stem cells apart from endothelial cells
express CD133. Other explanations may be methodological
differences (e.g., different pretreatment of sections prior to
immunostaining and different type of sections (paraffin
sections vs. frozen sections) [23].
Very few studies have investigated the relationship
between CD133 promoter hypermethylation and protein
expression in human glioma samples. In the present study,
there was an inconsistent correlation between aberrant
promoter methylation and loss of protein expression. To
date, this inconsistency was not limited to the CD133 gene
[32–35]. Promoter methylation is clearly involved in the
inactivation of CD133 gene in numerous tumors and cancer
cell lines [20, 21], but regulation of CD133 expression is a
more complex phenomenon in which abnormal methyla-
tion of the promoter is not the only determining factor [21,
36, 37]. Indeed, several studies indicate that grade of
methylation both in the promoter region and in neighboring
sequences may regulate gene expression [20, 37, 38]. As
discussed previously, another possible explanation for this
finding is CD133 protein expression in entrapped pre-ex-
isting endothelial cells, which is confirmed by flow
cytometry showing that CD133? cells could have either
blood vessel or glioma origin [39, 40]. Therefore, there is
increasing evidence that immunohistochemically assessed
CD133 expression is a poor indicator of CD133 promoter
methylation status in glioma.
However, the importance of this study goes beyond
showing the putative clinical benefit of CD133 methylation
status as a prognositic marker. Currently, little data exist on
the clinical relevance of CSCs. Properties of CSCs could
well explain many clinical features of cancer, such as
recurrence, and therapy resistance [1, 41–49]. Some studies
also tested whether the prevalence of putative CSCs in the
tumor was relevant to patient outcome, but the results were
controversial [23, 24, 30, 31, 50–54]. In light of the results
reported here, the discrepancy may seem not surprising
because different CSC markers, heterogenous expression,
and observation variability all effect on the results. Here,
for the first time, we presented a direct link between the
methylation of a CSC marker and patients’ outcome. These
data provide strong supportive evidence for the CSC model
and the clinical relevance of the CD133 methylation status
in gliomas.
To conclude, in our study, CD133 promoter methylation
status in glioma is closely correlated with patient survival,
which suggest CD133 promoter methylation pattern is a
promising tool for prognostic purposes. While, lack of
association with CD133 IHC and with patient survival
impede the use of CD133 IHC as a clinically useful bio-
marker for routine purposes and clinical decision making.
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